Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Vanda Teodoro"'
Autor:
Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Ronald J Bernardi, Víctor Jiménez-Yuste, Benjamin M Beckermann, Christophe Schmitt, Giuliana Ventriglia, Jerzy Windyga, Roseline d'Oiron, Paul Moorehead, Sunita Koparkar, Vanda Teodoro, Amy D Shapiro, Johannes Oldenburg, Cedric Hermans
Publikováno v:
The Lancet. Haematology, Vol. 10, no.3, p. e168-e177 (2023)
BACKGROUND: Clinical trial data are scarce for the use of prophylaxis in people with non-severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab prophylaxis in people with non-severe haemophilia A without factor VIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5495bafd43f5844c792ca78dc42aa24d
https://hdl.handle.net/2078.1/274140
https://hdl.handle.net/2078.1/274140
Autor:
Roseline d'Oiron, Anna Kiialainen, Vanda Teodoro, Jerzy Windyga, Johannes Oldenburg, Amy D. Shapiro, Cedric Hermans, Giuliana Ventriglia, Víctor Jiménez-Yuste, Paul Moorehead, Christophe Schmitt, Michaela Lehle, Benjamin M. Beckermann, Olivier Catalani, Claude Negrier, Johnny Mahlangu, Pratima Chowdary
Publikováno v:
Blood. 138:343-343
Background: Emicizumab, a bispecific monoclonal antibody, bridges activated factor (F)IX and FX, substituting for the function of missing activated FVIII in persons with hemophilia A (HA). The HAVEN 6 study (NCT04158648) aims to assess the safety, ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb0cd5ad937007b124c3d8f8c7d7970a
https://doi.org/10.1182/blood-2021-146009
https://doi.org/10.1182/blood-2021-146009
